Don Tracy, Associate Editor

In an interview with Pharma Commerce Associate Editor Don Tracy, John Hoffman, Principal, Advocate for Success, LLC offers his thoughts on the Inflation Reduction Act and discusses current advocacy efforts.

In an interview with Pharma Commerce Associate Editor Don Tracy, Amy Niles, Chief Mission Officer, PAN Foundation offers her thoughts on the session and feedback from the audience at PAP 2024 in Philadelphia.

In an interview with Pharma Commerce Associate Editor Don Tracy, Monique French, MPH, Senior Director, Patient Advocacy, Health Policy & Communications, Rx4Good provides insight on engaging multiple healthcare groups.

In an interview with Pharma Commerce Associate Editor Don Tracy, Michael Galarraga, LPC, ATR-BC, Pennsylvania State Representative, OutCare Health offers his thoughts on the breakout session and his experience in mental health counseling.

In an interview with Pharma Commerce Associate Editor Don Tracy, John Hoffman, Principal, Advocate for Success, LLC talks about his 'Health Equity Spotlight' panel and advocacy accomplishments.

Xhance is the first medication indicated for the treatment of chronic rhinosinusitis without nasal polyps to be approved by the FDA.

Approval was based on positive data from the Phase III MARCH study across a range of genetic progressive familial intrahepatic cholestasis types.

In an interview with Pharma Commerce Associate Editor Don Tracy, Corey Ford, VP, Reimbursement & Policy Insights, Cencora, offers his thoughts on where the Inflation Reduction Act will be five to 10 years from now.

In an interview with Pharma Commerce Associate Editor Don Tracy, Corey Ford, VP, Reimbursement, Policy Insights, Cencora, provides a look at his recent webinar focused on the implications of the Inflation Reduction Act.

Personalized medicine approaches, informed by predictive modeling, could optimize treatment outcomes and reduce patient burden and costs.

The Masimo product is expected to address a significant gap in the market for dependable home-use medical devices.

Powered by evidence from the TRILUMINATE trial, Abbott's TriClip System’s benefits outweighed its risks, which led to the group’s positive recommendation.

Patients with severe frostbite who were administered Aurlumyn monotherapy experienced a significantly reduced risk of the need for amputation.

New collaboration seeks to take a significant step in the development of targeted treatments for solid tumors and an expansion of opportunities in the growing antibody-drug conjugate market.

DELFI-TF assay shows promise in evaluating treatment response and resistance to immunotherapies in patients with advanced cancers.

Rusfertide could potentially be a first-in-class, transformational treatment for polycythemia vera.

In an interview with Pharma Commerce associate editor Don Tracy, Lynn Kirkpatrick, PhD, CEO, Ensysce Biosciences, discusses the FDA's Breakthrough Therapy Designation for PF614-MPAR, which focuses on protecting patients from drug overdoses.

In an interview with Pharma Commerce Associate Editor Don Tracy, Ron Lanton, Partner, Lanton Law PLLC, discusses recent moves by CVS and Express Scripts to follow Mark Cuban's drug plus model.

Concerns regarding hypoglycemia potentially linked to a counterfeit version of Ozempic come at a time in which reports have grown regarding the improper use of GLP-1 receptor agonists for the purpose of cosmetic weight loss.

Patients treated with Tremfya (guselkumab) saw major improvements in scalp psoriasis clearance, itch reduction, and patient-reported health-related quality of life.

Offerings include treatment plans for a considerable number of illnesses and conditions, company says.

NK010, which showed promising anti-tumor activity and safety in preclinical studies, will be evaluated in a Phase I clinical trial for ovarian cancer.

Phase Ib study evaluated satri-cel in patients with advanced gastric/gastroesophageal cancer or pancreatic cancer who had progressed on or were intolerant of prior systemic therapy.

Opdivo (nivolumab) with Yervoy (ipilimumab) showed a 79% drop in the risk of disease progression or death compared to chemotherapy in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer.

Bloomlife’s MFM-Pro enables healthcare providers to measure maternal and fetal heart rate in the patient's home or clinic.

Researchers from the University of Cambridge collaborated with Pfizer to develop a platform combining automated experiments with artificial intelligence to predict chemical reactions.

Zoryve (roflumilast) shows efficacy in seborrheic dermatitis and atopic dermatitis in clinical trials.

Roots Analysis report suggests increase can be attributed to the growing demand for advanced therapies and biologics.

Breakout session summarizes key areas that will affect all aspects of the industry.

PrEPVacc tested two different combinations of vaccines to determine whether either can prevent HIV infection in populations at risk of acquiring the virus.